- Previously served as Senior Vice President, Global Product and Supply Chain Management at Genentech, Inc. (Roche)
- Brings more than 25 years of biopharma operations experience to Dermira
MENLO PARK, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the appointment of Christopher Horan as Chief Technical Operations Officer. In this newly created role, Chris will oversee pharmaceutical sciences, procurement, supply chain, including contract manufacturing, and quality as Dermira prepares to commercialize glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration (FDA) for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and advance the development of lebrikizumab, currently being studied in Phase 2b for the treatment of moderate-to-severe atopic dermatitis.
“Chris brings a wealth of technical operations experience to Dermira and we are delighted that he is joining at a critical moment for the company as we prepare to bring our first treatment to patients,” said Tom Wiggans, chairman and chief executive officer of Dermira. “His broad experience managing external manufacturing and supply chain will ensure that we drive the operational excellence necessary to reliably deliver high-quality products to people living with skin conditions.”
Chris joins Dermira from Genentech where he spent nearly 14 years in roles of increasing responsibility within its Operational Excellence, Supply Chain, Procurement and Technical Operations functions. He most recently served as Senior Vice President, Global Product and Supply Chain Management at Genentech (a member of the Roche Group), where he led a team supplying all Roche biopharma products worldwide. Prior to Genentech, he worked for Merck & Company in global roles across Engineering, Manufacturing and Operational Excellence.
“I am thrilled to be joining Dermira at a pivotal moment for the company as we continue to develop our manufacturing and supply chain capabilities in preparation for the potential launch of glycopyrronium tosylate,” said Horan. “Dermira’s patient-centered, science-driven culture is a great fit and strong attraction for me. I look forward to contributing to the company’s commercial success.”
Chris, who holds a BE in Engineering from the Stevens Institute of Technology, will serve on the executive management committee.
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow Dermira on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc-) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.
The information in this news release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This news release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to potential FDA approval of glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis; the advancement of development of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis; commercialization of Dermira’s product candidates; Dermira’s ability to reliably deliver high-quality products to people living with skin conditions; Dermira’s plans to develop its manufacturing and supply chain capabilities; and Dermira’s anticipated commercial efforts and successes. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials; the outcomes of Dermira’s future meetings with regulatory agencies; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to attract and retain key employees; Dermira’s ability to obtain necessary additional capital; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this news release. Dermira undertake no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
Vice President, Corporate Communications
Ian Clements, Ph.D.
Vice President, Investor Relations
Robert H. Uhl
Source: Dermira, Inc.